Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
暂无分享,去创建一个
G. Salles | F. Berger | A. Stamatoullas | N. Mounier | O. Reman | P. Lederlin | P. Brice | P. Colin | L. Voillat | J. Jaubert | M. Diviné | C. Fermé | M. Diviné
[1] V. Diehl,et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. , 2000, Blood.
[2] F. Berger,et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial. , 2000, Blood.
[3] B. Coiffier,et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P Dirschedl,et al. Analysis of time-dependent covariates in failure time data. , 1999, Statistics in medicine.
[5] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[6] R. Bouabdallah,et al. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry , 1998, Bone Marrow Transplantation.
[7] S. Horning,et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. , 1997, Blood.
[8] S. Horning,et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.
[9] I. Tannock,et al. False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. , 1996, Journal of the National Cancer Institute.
[10] D. Reece,et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. , 1995, Blood.
[11] F. Berger,et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Nademanee,et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. , 1995, Blood.
[13] D. Reece,et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.
[14] N. Schmitz,et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Hagenbeek,et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. A. Tanner,et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Maslak,et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.
[19] R. Chopra,et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.
[20] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.
[21] E. Jaffe,et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Hillner,et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Bacigalupo,et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.
[24] J. Armitage,et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Connors,et al. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. , 1988, Seminars in hematology.
[26] W. Velasquez,et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Connors,et al. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[29] V. Diehl,et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Coiffier,et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Gribben,et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. , 1989, Blood.
[32] D. Cox. Regression Models and Life-Tables , 1972 .